

February 05, 2020

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec Limited completes transfer of its Pharmaceuticals Business to its wholly owned subsidiary “Panacea Biotec Pharma Limited”

Dear Sir,

Panacea Biotec Ltd. is pleased to announce that the company has completed transfer of its Pharmaceuticals Business by way of slump sale (as a going concern) to its wholly-owned subsidiary viz. Panacea Biotec Pharma Limited (“PBPL”), with an objective to streamline operations and create inherent focus among the businesses of the Company.

PBPL obtained the drug manufacturing license on February 01, 2020. Pursuant to above and in compliance with the terms and conditions of the BTA, the transfer of the Company’s pharmaceuticals business to PBPL by way of slump sale as a going concern has become effective from February 1, 2020. The documents relating to closing of transaction as above were executed on February 4, 2020.


A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

For Panacea Biotec Limited


Vinod Goel
Group CFO and Head Legal
& Company Secretary



Encl: as above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

New Delhi, February 5, 2020

Panacea Biotec Limited completes transfer of its Pharmaceuticals Business to its wholly owned subsidiary “Panacea Biotec Pharma Limited”

Panacea Biotec Limited (“the **Company**”), one of India’s leading pharmaceutical and biotechnology companies today announced that it has completed transfer of its Pharmaceuticals Business by way of slump sale (as a going concern) to its wholly-owned subsidiary viz. Panacea Biotec Pharma Limited (“**PBPL**”), with an objective to streamline operations and create inherent focus among the businesses of the Company.

Earlier, on February 26, 2019, as part of the business reorganization, the Board of Directors of the Company approved transfer of the pharmaceutical business by way of slump sale (as a going concern) to PBPL. The divestment was approved by the shareholders of the Company in their extra-ordinary general meeting held on March 25, 2019. In order to implement the above transfer, the Company had executed a Business Transfer Agreement (“**BTA**”) with PBPL on April 7, 2019.

PBPL obtained the drug manufacturing license on February 01, 2020. Pursuant to above and in compliance with the terms and conditions of the BTA, the transfer of the Company’s pharmaceuticals business to PBPL by way of slump sale as a going concern has become effective from February 1, 2020. The documents relating to closing of transaction as above were executed on February 4, 2020.

About Panacea Biotec

Panacea Biotec is a leading pharmaceutical and biotechnology company with established Research, Manufacturing and Marketing capabilities. The Company is amongst the top 15 pharmaceutical companies in its represented market in India and amongst top 60 pharmaceutical Companies in India (AIOCD AWACS-MAT MAR-2019). The Company has been awarded with the prestigious “India Innovation Award – Top 50” by Clarivate Analytics (Thomson Reuters) for the years 2015 & 2016.

The product portfolio includes innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric vaccines. The Company is working on a robust pipeline of high barrier to entry



Page 1 of 2

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

generics products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastro-retentive systems.

It has introduced its products in around 30 countries across the world, including USA, Germany and Russian Federation, through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations. The company has around 2400 employees.

For more information, please contact:

For Investors	For Media
<p>Mr. Devender Gupta Chief Financial Officer and Head Information Technology Tel: + 91-11-41679000 Ext. 1225, 41578011 (Direct) Mobile: +91 98109 04102 Email: devendergupta@panaceabiotec.com</p>	<p>Mr. P. D. Karan Vice President - Corporate Communication & Business Development Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct) Mobile: + 91 9312693040, + 91 9810500539 Email: pdkaran@panaceabiotec.com</p>

